Skip to content

Ginkgo Bioworks DNA Current maturities of long-term debt

Current maturities of long-term debt at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Ginkgo Bioworks’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's current maturities of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's current maturities of long-term debt?
Ginkgo Bioworks (DNA) reported current maturities of long-term debt of $20K in Q4 2025.
What is the long-term trend for Ginkgo Bioworks's current maturities of long-term debt?
Over 3 years (2022 to 2025), Ginkgo Bioworks's current maturities of long-term debt has grown at a -75.1% compound annual growth rate (CAGR), from $1.3M to $20K.